Current ratings for: Advanced-stage ovarian cancer treated with targeted nanomedicine
Ratings require JavaScript to be enabled.
Researchers at Rutgers, the State University of New Jersey, have used a targeted nanomedicine approach to deliver small molecule drugs and successfully treat mice with deadly advanced-stage ovarian cancer.
Writing about their work in a recent print issue of the journal Clinical Cancer Research, the team explains how an out-of-control protein called CD44 aids tumor growth and development of drug resistance in advanced-stage ovarian cancer.
Ovarian cancer is the deadliest gynecological cancer in the United States. The National Cancer Institute estimates there will be 22,240 new cases and 14,030 deaths due to the disease in 2013.
It is not easy to spot ovarian cancer in the early stages, and there is no effective screening method, so most women do not find out they have it until after it has spread to other organs. By this stage, surgery and chemotherapy are not as effective.
The 5-year survival rate for patients with advanced-stage ovarian cancer is 30%. The researchers believe this is mainly because of the activity of the aberrant CD44 protein and its ability to make the late stage of the disease resistant to drugs.
Study author Dr. Lorna Rodriguez, a gynecologic oncologist and director of the precision medicine initiative at Rutgers Cancer Institute of New Jersey, explains:
"Once the ovarian cancer becomes drug resistant we cannot cure it. Circumventing the development of drug resistance is a reasonable approach and very much needed."
In their study paper, the researchers describe how they used small molecules, called inhibiting RNA molecules, to attack the genes of the excess CD44 protein in metastatic ovarian cancer cells isolated from patients.
Visit link:
Advanced-stage ovarian cancer treated with targeted nanomedicine